Inicio › Cáncer de seno › Indiana › Indianapolis
Ensayos clínicos de Cáncer de seno en Indianapolis, IN
20 estudios para Cáncer de seno buscan participantes en centros de Indianapolis y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
ReclutandoFase 3
- Community Health Network, Inc, Indianapolis
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
ReclutandoFase 3
- Investigative Clinical R of Indiana, Indianapolis
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
ReclutandoFase 2Se aceptan voluntarios sanos
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
ReclutandoFase 1
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
ReclutandoFase 1/2
- Community Health Network, Indianapolis
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
ReclutandoFase 3
- Franciscan Health ( Site 0077), Indianapolis
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Reclutando
- Indiana University, Indianapolis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
ReclutandoFase 1
- Indiana University (IU) School of Medicine, Indianapolis
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
ReclutandoFase 3
- Indiana University Health University Hospital, Indianapolis
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
ReclutandoFase 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
ReclutandoFase 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
ReclutandoFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- Community Cancer Center East, Indianapolis
- y 5 más
HER2 Vaccine for Locally Advanced Breast Cancer
ReclutandoFase 1
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis
Exercise in Metastatic Breast Cancer: EMBody
Reclutando
- Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
ReclutandoFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Health Mooresville, Mooresville · A 16 mi de distancia
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
ReclutandoFase 2
- Indiana University, Indianapolis
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
ReclutandoFase 1/2
- Research Site, Indianapolis
NearWave Optical Molecular Monitoring
Reclutando
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
ReclutandoFase 3
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Health Mooresville, Mooresville · A 16 mi de distancia
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
ReclutandoFase 1
- Community Health Network, Indianapolis
Más información sobre Cáncer de seno en MedlinePlus
Ensayos de Cáncer de seno en otras ciudades
- New York City, NY136 estudios
- Houston, TX126 estudios
- Boston, MA112 estudios
- Nashville, TN81 estudios
- Los Angeles, CA73 estudios
- Edison, NJ68 estudios
- St. Louis, MO64 estudios
- Queens, NY64 estudios
- Durham, NC64 estudios
- Chicago, IL59 estudios
- Philadelphia, PA56 estudios
- Dallas, TX55 estudios
Otros estudios en Indianapolis
- Cáncer de pulmón de células no pequeñas32 estudios
- Cáncer (todos los tipos)24 estudios
- Fallo cardíaco23 estudios
- Obesidad20 estudios
- Cáncer metastásico19 estudios
- Cáncer del colon y del recto18 estudios
- Cáncer de ovario17 estudios
- Enfermedad cardiovascular17 estudios
- Cáncer de pulmón16 estudios
- Diabetes tipo 114 estudios
- Cáncer de endometrio14 estudios
- Enfermedad de Alzheimer14 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.